# tirzepatide

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/tirzepatide-product
Canonical HTML page: https://gethealthbrief.com/entity/tirzepatide-product

## Timeline

- **2026-04-14**: JPM Q1 Earnings Report — JPMorgan Chase reports first-quarter financial results amidst regulatory and legal scrutiny.
- **2026-04-10**: FDA Orforglipron Decision — Expected regulatory ruling on Eli Lilly's oral GLP-1 candidate for weight loss.
- **2026-03-12**: Impurity Discovery — Lilly announces discovery of impurities in compounded samples and issues safety warnings.
- **2025-Q4 (projected)**: Shortage Resolution — Expected timeframe for tirzepatide to be removed from FDA shortage list, ending legal compounding.
- **2025-03-13**: Impurity Warning — Lilly issues formal warning after testing reveals bacterial contamination in compounded samples.
- **2024-02-15**: Initial Lawsuits — Lilly begins filing legal actions against medspas for trademark infringement.
- **2024-Q1**: Shortage Surge — Widespread shortages lead to a massive increase in compounding pharmacy production.
- **2023-11**: Zepbound Approval — FDA approves Zepbound for chronic weight management.
- **2023-05-01**: Shortage Begins — FDA adds tirzepatide to the official drug shortage list, enabling compounding.
- **2022-05**: Mounjaro Approval — FDA approves Mounjaro for Type 2 diabetes treatment.

## Recent coverage (4 stories)

### April Catalysts: Eli Lilly’s Oral GLP-1 Decision and JPM Earnings Outlook
2026-03-23 00:14:25 · Sentiment: Positive · Impact: 7/10 · Sources: 5

Investors are monitoring two critical mid-April deadlines: the FDA's decision on Eli Lilly's oral weight-loss drug, orforglipron, and JPMorgan Chase's first-quarter earnings report. These events serve as key indicators for the pharmaceutical sector's obesity market expansion and the banking sector's regulatory resilience.
Full story: https://gethealthbrief.com/story/eli-lilly-jpmorgan-april-catalysts-analysis

### Lilly Warns of Impurities in Compounded Weight-Loss Drugs Amid Safety Concerns
2026-03-13 20:21:25 · Sentiment: Negative · Impact: 7/10 · Sources: 23

Eli Lilly has issued a formal warning regarding the discovery of impurities in compounded versions of its popular weight-loss treatments. The pharmaceutical giant highlighted significant safety risks associated with these unapproved alternatives, which have proliferated during ongoing supply shortages.
Full story: https://gethealthbrief.com/story/lilly-warns-impurities-compounded-weight-loss-drugs

### Eli Lilly Warns of Impurities in Compounded Versions of Weight-Loss Drugs
2026-03-13 01:00:40 · Sentiment: Negative · Impact: 7/10 · Sources: 2

Eli Lilly has issued a formal warning after discovering impurities in compounded versions of its blockbuster weight-loss medication. The pharmaceutical giant cautioned that these unapproved formulations pose significant health risks to patients seeking alternatives during supply shortages.
Full story: https://gethealthbrief.com/story/lilly-warns-compounded-tirzepatide-impurities

### Pharma Giants and AI Disruptors: Top Healthcare Growth Stocks for 2026
2026-03-04 04:09:39 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions.
Full story: https://gethealthbrief.com/story/healthcare-growth-stocks-2026-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.